Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)

Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.

NCT Number	NCT05697588
Lead Sponsor	Cuibai Wei，Clinical Professor Collaborators: Beihang University, Chinese PLA General Hospital, Chongqing Medical University, Tianjin Huanhu Hospital, Affiliated Zhongshan Hospital of Dalian University, First Hospital of Shijiazhuang City, Jilin University
Conditions	Biomarkers, MCI Conversion to Dementia
Enrollment	900 participants
Start Date	2023-02-28
Primary Completion	2028-02-28 (estimated)
Study Completion	2028-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-07-24